About FOXO Technologies
FOXO Technologies is a publicly listed company based in Minneapolis (United States) founded in 2020. Epigenetic biomarkers are discovered and developed via AI platforms. It operates on a HealthTech and Managed Services model. FOXO Technologies offers products and services including Epigenetic Diagnostics, Rural Hospitals, and Mental Health Facilities. Its focus areas include Biotechnology, Diagnostics, Hospitals and Rural Healthcare. Its legal entity is FOXO Technologies, Inc. Its competitors include Chroma Medicine, Reaction Biology and Epinoma; 2 of its 3 listed competitors have raised funding.
Company details
FOXO Technologies, Inc. is involved in healthcare services and technology through three divisions. Epigenetic diagnostics and interpretation are provided for advanced health insights. Rural hospitals are operated to address community healthcare needs. Mental and behavioral health facilities are managed to support patient well-being. Each division is run by wholly owned subsidiaries, focusing on innovation-driven solutions for critical healthcare provider needs across various sectors.
- Headquarters Minneapolis, United States
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website foxotechnologies.com
- Legal Name Foxo Technologies Inc.
- Annual Revenue$16.41 M (USD)308.26as on Dec 31, 2025
- Net Profit-$12.43 M (USD)-0.19as on Dec 31, 2025
- Latest Funding Round$1.65M (USD), Post-IPO
Jun 2025
- Investors
Products & Services of FOXO Technologies
FOXO Technologies offers a comprehensive portfolio of products and services, including Epigenetic Diagnostics, Rural Hospitals, and Mental Health Facilities.
Epigenetic diagnostics are provided for health insights and analysis.
Rural hospitals are operated to serve community health needs.
Mental health facilities are managed for behavioral health support.
Funding Insights of FOXO Technologies
- Total Rounds 11
- Last Round Post-IPO — $1.65M
- First Round $10.5M
(Feb 2021)
- Investors Count 1
Latest 10 of 11 funding rounds of FOXO Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | $1.65M | Post-IPO | – | – | – |
| May 2025 | $1.1M | Post-IPO | – | – | – |
| Apr 2025 | $275,000 | Post-IPO | – | – | – |
| Apr 2025 | $325,000 | Post-IPO | – | – | – |
| Dec 2024 | $110,000 | Post-IPO | – | – | – |
| Nov 2024 | $220,000 | Post-IPO | – | – | – |
| Jul 2024 | $290,493 | Post-IPO | – | – | – |
| Mar 2024 | $110,000 | Post-IPO | – | – | – |
| Jan 2024 | $457,470 | Post-IPO | – | – | – |
| Jun 2023 | $2.47M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in FOXO Technologies
FOXO Technologies has secured backing from 1 investor. Prominent investors backing the company include Bespoke Growth Partners, Inc.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| 123bgp.com |
Investor details for FOXO Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of FOXO Technologies
6 people are tracked at FOXO Technologies (1 in leadership, 3 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Murdoc Khaleghi | Board Of Directors, Chief Medical Officer | Leadership |
Peter Laird | Scientific Advisory Board Member | Board & advisors |
Bret Barnes | Scientific Advisory Board Member | Board & advisors |
Hui Shen | Scientific Advisory Board Member | Board & advisors |
Carley Anderson | Operations Associate | Team |
Brenda Lidke | Financial Consultant | Team |
Complete people profiles for FOXO Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of FOXO Technologies
FOXO Technologies is a publicly listed company on the OTC with ticker symbol FOXO in USA, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Jan 2021
- Listed onNYSEAMERICAN: FOXO
- Listed entityFOXO Technologies Inc.
- Exchange sectorTechnology services
- ISINUS3514716022
- Share price$0.11 (+4.46% on the day) · 2026-10-12
- Market capitalisation$178,745.00
- EPS (diluted, trailing year)$-649.59
- Volume (last session)2,911
Financials of FOXO Technologies
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $16.4M | -$12.4M | |
| 2024 | $4.0M | -$12.4M | |
| 2023 | $447,830 | -$26.4M | |
| 2022 | -$52.9M | -$95.2M | |
| 2021 | -$21.6M | -$38.5M |
Detailed financial statements for FOXO Technologies
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of FOXO Technologies
4 dated milestones of FOXO Technologies across 5 years, from founding to its latest funding, stage changes and deals.
- Founded FOXO Technologies is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $10.5M.
- Funding Latest funding round, Post-IPO, of $1.6M.
Competitors of FOXO Technologies
FOXO Technologies has 3 listed competitors in our database, 2 of them funded. They include Chroma Medicine, Reaction Biology and Epinoma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| chromamedicine.com | 2020 | Cambridge, United States | $135M | 122 | Epigenetic editing platform is developed for genomic medicines. | |
| reactionbiology.com | 2001 | United States | 77 | In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling | ||
| epinoma.com | 2020 | San Carlos, United States | $125,000 | 4 | Limited information available |
Detailed competitors of FOXO Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of FOXO Technologies
The website of FOXO Technologies (foxotechnologies.com) receives about 3.4K visits a month.
- Monthly visits3.4K
▲ 15.3% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as FOXO Technologies (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Foxo Technologies
Complete news archive for FOXO Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about FOXO Technologies
FOXO Technologies was founded in 2020 and raised its 1st funding round 1 year after it was founded.
FOXO Technologies is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
Annual revenue of FOXO Technologies is $16.41M as on Dec 31, 2025.
FOXO Technologies, Inc. is involved in healthcare services and technology through three divisions. Epigenetic diagnostics and interpretation are provided for advanced health insights. Rural hospitals are operated to address community healthcare needs. Mental and behavioral health facilities are managed to support patient well-being. Each division is run by wholly owned subsidiaries, focusing on innovation-driven solutions for critical healthcare provider needs across various sectors.
FOXO Technologies's top competitors include Chroma Medicine, Reaction Biology and Epinoma.
FOXO Technologies offers Epigenetic Diagnostics, Rural Hospitals, and Mental Health Facilities.
Yes, FOXO Technologies is publicly traded on OTC under the ticker symbol FOXO.
FOXO Technologies has 1 investor. Key investors include Bespoke Growth Partners, Inc.
FOXO Technologies operates through Foxo Technologies, Inc..